Activated protein C was cost-effective for prolonging survival in a subgroup of patients with severe sepsis
- Recombinant human activated protein C in severe sepsis. Mann, Henry J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19
Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in...
- Fresh from the pipeline: Drotrecogin alpha (activated). Lebbos, John; Bradsher, Julia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p13
In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet...
- Activated Protein C for Sepsis. Mackenzie, Alasdair // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150
A letter to the editor is presented in response to the article "Activated Protein C for Sepsis," by S. Toussaint et al. published in the December 31, 2009 issue.
- Activated Protein C for Sepsis. Toussaint, Susanne; Gerlach, Herwig // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150
A response by Susanne Toussaint and Herwig Gerlach to a letter to the editor about their article "Activated Protein C for Sepsis" in the December 31, 2009 issue is presented.
- Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Pastores, S.M. // Postgraduate Medical Journal;Jan2003, Vol. 79 Issue 927, p5
Focuses on the role of activated drotrecogin alfa, referred to as recombinant human activated protein C in the treatment of severe sepsis. Clinical features of severe sepsis; Relation of activation of the coagulation system and the inflammatory response in the pathophysiology of severe sepsis;...
- Drotrecogin Alfa (Activated): A Viewpoint by Derek C. Angus. Angus, D.C. // Drugs;2002, Vol. 62 Issue 4, p631
Examines the efficacy of drotrecogin alfa in reducing the mortality of patients with severe sepsis. Role of endogenous activated protein C in sepsis; Benefits and adverse effect of drotrecogin alfa therapy; Limited data on patient-centered outcomes associated with therapy.
- Managing high-cost biotechnology products. Wong, Dorothy H.; Yang, Peggy // American Journal of Health-System Pharmacy;6/15/2003, Vol. 60 Issue 12, p1213
Offers ways to ensure the appropriate use of Drotrecogin alfa, a recombinant human activated protein C with U.S. Food and Drug Administration-approved labeling for use in the treatment of severe sepsis in adult. Medication-related issues; Criteria for use; Medication-use evaluation to track...
- P & T PORTFOLIO. // Drug Topics;2/18/2002, Vol. 146 Issue 4, p16
Evaluates the recombinant form of human protein C, Drotrecogin alfa for reducing mortality in adult patients with severe sepsis. Efficacy of the drug; Pharmacology; Warnings related to use.
- Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi. Levi, M. // Drugs;2002, Vol. 62 Issue 4, p631
Examines the therapeutic use of protein C in the treatment of sepsis. Role of microvascular thrombosis in organ failure and mortality in patients with sepsis; Beneficial effect of activated protein C; Strategies to reduce mortality from sepsis.